LAB Standard BioTools Inc.
USHealthcareAs of 2026-07-10 16:00
Why LAB matters now
Standard BioTools Inc. (LAB) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.92 with -2.07% on the session and $359.5M in market capitalization; recent performance reads 1-month -17.03% and YTD -35.18%.
The latest financial table shown here is Q1 2026, with revenue of $21.1M, net income of $-45.2M, and EPS of $-0.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -29.2%.
The latest indexable market news headline is "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.25; recent insider activity includes Egholm Michael filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.57
P/S
3.75
EV/EBITDA
-1.07
DCF Value
$-1.43
FCF Yield
-29.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.3%
Operating Margin
-91.0%
Net Margin
-109.1%
ROE
-20.8%
ROA
-14.7%
ROIC
-7.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $21.1M | $-45.2M | $-0.12 |
| Q4 2025 | $23.8M | $19.3M | $0.05 |
| FY 2025 | $85.3M | $-74.9M | $-0.20 |
| Q3 2025 | $19.6M | $-34.7M | $-0.09 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$3.25
Target (Median)
$3.25
Target Range
$3.25 - $3.25
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.38
Standard BioTools Inc., established in 1999 and based in South San Francisco, California, is a key player in providing advanced scientific tools. Formerly known as Fluidigm Corporation until its name change in April 2022, the company designs, produces, and distributes a variety of instruments, specialized consumables, and support services. These offerings cater to biomedical researchers and scientists worldwide, including those in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, assisting them in the creation of new therapeutics. The company operates through two main divisions: Proteomics and Genomics. Within these areas, it supplies instruments, disposable products, software, and services that enable the identification and functional analysis of proteins and genes. Standard BioTools’ innovative product line includes several advanced platforms: The SomaScan platform allows for the simultaneous measurement of numerous proteins, yielding extensive insights into biological pathways and disease progression. The CyTOF technology platform utilizes metal-tagged antibodies with time-of-flight mass spectrometry to overcome signal interference and boost multiplexing capabilities. Hyperion is a spatial biology platform that facilitates a deeper comprehension of tissue architecture by preserving spatial context while conducting high-dimensional molecular and proteomic analyses. The Biomark X9 system transforms high-throughput genomics, specifically designed for quantitative polymerase chain reaction (qPCR) applications. These instruments and consumables are intended strictly for research purposes. Standard BioTools serves a broad spectrum of clients, including academic research institutions, centers for translational research and medicine, cancer centers, clinical research laboratories, and companies in the biopharmaceutical, biotechnology, and plant/animal research industries. Furthermore, the company has established licensing agreements with prominent organizations such as the California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc.